Selank Research

Zozulia AA, Neznamov GG, Syunyakov TS, et al.

The primary human clinical trial of Selank — a comparative study of 62 patients with generalized anxiety disorder (GAD) and neurasthenia, treated with either Selank (30 patients) or medazepam, a benzodiazepine (32 patients). Assessed using Hamilton, Zung, and CGI psychometric scales, Selank produced anxiolytic effects comparable to medazepam — but with additional antiasthenic (anti-fatigue) and psychostimulant effects not seen with the benzodiazepine. Critically, Selank produced these effects without the typical benzodiazepine side effects of sedation, muscle relaxation, dependence, or withdrawal syndrome. This study is the primary evidence base for Selank’s clinical use in Russia and the foundation of its reputation as a “cleaner” alternative to benzodiazepines.

Volkova A, Shadrina M, Kolomin T, et al.

A molecular study investigating how Selank produces its anxiolytic effects — specifically whether it acts through the GABA system like benzodiazepines. The study examined mRNA levels of 84 genes involved in GABAergic neurotransmission in rat frontal cortex. The findings confirmed that Selank affects the GABA system — but indirectly, through allosteric modulation of GABAA receptors rather than direct binding. This distinction is important: direct GABA receptor agonism (as with benzodiazepines) produces tolerance and dependence, while allosteric modulation is associated with a much lower dependence risk. The study also found that Selank’s gene expression profile closely paralleled that of GABA itself — explaining the mechanistic similarity without the side effect profile.

Semenova TP, Kozlovskiy II, Zakharova NM, et al.

A preclinical study examining how Selank interacts with diazepam (Valium) under chronic stress conditions — with significant implications for potential clinical use in anxiolytic therapy. The study found that Selank alone was most effective at reducing anxiety induced by repeated substance administration, while the combination of Selank and diazepam was most effective under unpredictable chronic mild stress — with anxiety levels returning to pre-stress baseline. The synergistic effect suggests Selank may enhance and hasten the onset of benzodiazepine therapy while potentially reducing the dose required and mitigating some side effects — a clinically meaningful finding for anxiety disorder treatment.

Kolik LG, Nadorova AV, Antipova TA, et al.

A study examining Selank’s neuroprotective effects in a model of chronic alcohol-related cognitive decline. Rats exposed to 10% ethanol for 30 weeks developed memory and attention impairments — but Selank treatment (0.3 mg/kg daily for 7 days) prevented these deficits and also produced a cognitive-stimulating effect in non-alcohol-exposed control animals. Selank prevented ethanol-induced dysregulation of BDNF in both the hippocampus and prefrontal cortex — the two brain regions most critical for memory and executive function. This study extends Selank’s research profile beyond anxiety into neuroprotection and cognitive preservation, linking its effects to the same BDNF mechanism identified in Semax research.

Dadayan AK, et al.

A cell-based study examining Selank’s interaction with both GABA and the antipsychotic olanzapine — exploring its potential as an adjunct in psychiatric treatment. The study found that combining Selank with GABA nearly completely suppressed the gene expression changes that GABA alone produced — suggesting Selank allosterically modulates GABA receptor affinity rather than acting as a direct agonist. More intriguingly, combining Selank with olanzapine amplified gene expression changes compared to olanzapine alone — suggesting Selank may enhance the effectiveness of antipsychotic medication through BDNF-mediated pathways. These findings open a potential research direction for Selank as an adjunct in schizophrenia and other psychiatric conditions.